Kenneth Weg

Sep 10, 2015

Metamark Genetics has appointed Kenneth Weg as president and CEO. He succeeds Shawn Marcell, who resigned from his position to pursue other activities. Weg is a Metamark co-founder and current chairman of the board of directors. He has previously served as the president of the Worldwide Medicines Group at Bristol-Myers Squibb (BMS), where he was responsible for overseeing all ethical pharmaceuticals and over-the-counter medicines on a global basis. Weg also served as vice chairman of the BMS board of directors. Before his work at BMS, he held the position of non-executive chairman of Millennium Pharmaceuticals. He has also served on the boards of Fox Chase Cancer Center and AVEO Pharmaceuticals and is a current member of Karyopharm's board of directors.

More Like This

Apr 27, 2017

Tina Nova

OpGen has appointed Tina Nova to its board of directors. Nova currently serves as president and CEO of newly formed molecular diagnostics company Molecular Stethoscope, and most recently served as senior vice president and general manager of Illumina's oncology business unit. From 2000 to 2014, Nova was cofounder, director, president, and CEO of Genoptix Medical Laboratory, which was purchased by Novartis for nearly $500,000 in 2011. She has also held senior positions with Nanogen, Ligand Pharmaceuticals, and Hybritech. She currently serves on the board of Arena Pharmaceuticals and Veracyte, and is vice chairman of the board for the newly formed Rady Pediatric Genomics and Systems Medicine Institute.

Apr 26, 2017

Rich Gray

N-of-One has appointed Rich Gray as VP of business development. In this position, he will lead both direct and channel sales teams to further develop channel partnerships to provide clinical interpretation on a broader scale. Gray joins N-of-One after serving various executive sales and market roles at organization such as Altos, now part of Flatiron Health; IntelliDose division of IntrinsiQ, now a division of AmerisourceBergen; and Medical Systems Management, now part of Optum.

Apr 26, 2017

Jamie L’Heureux

Progeny Genetics, a Delray Beach, Fla-based subsidiary of Ambry Genetics, has promoted Jamie L’Heureux to CEO. L'Heureux had been a software project manager at the company since 2014 and was a contractor for Progeny for two years before than. She has a total of 12 years of experience as a board-certified genetic counselor.

Apr 25, 2017

Vicki DiFrancesco

Xifin has appointed Vicki DiFrancesco its chief strategy officer. DiFrancesco has more than 25 years of experience in executive leadership positions and was most recently president and CEO of Pathology Inc., a women's health laboratory acquired by Laboratory Corporation of America last year. 

Apr 20, 2017

Bill Bonello

NeoGenomics has appointed Bill Bonello as VP, treasurer, and director of corporate development. Prior to joining NeoGenomics, Bonello served as senior research analyst at Craig Hallum Capital Markets, and as senior research analyst for RBC Capital Markets. He has also served as senior VP of investor relations for Laboratory Corporation of America, managing director of equity research at Wachovia Capital Markets, and managing director of equity research at Piper Jaffray.

Apr 18, 2017

Mark Boguski

Inspirata has appointed Mark Boguski to the role of chief medical officer for precision medicine. He will oversee strategic planning and implementation of the firm's precision medicine solutions. Prior to joining Inspirata in September 2016, Boguski served as CMO and cofounder of Precision Medicine Network, where he created a molecular oncology knowledge visualization and decision support platform called Crosswalk Insight: Oncology.

Apr 17, 2017

Jordan Hubbard

Jordan Hubbard has joined Two Pore Guys as vice president of engineering, where he will oversee the development of software and hardware for the company's nanopore-based single-molecule biosensor. Previously, Hubbard served as a manager and director of engineering at Apple, and headed up the FreeBSD project, an open-source UNIX variant that became a core technology in Apple's products.

Apr 13, 2017

David Schenkein

David  Schenkein has told the board of Foundation Medicine he will not stand for reelection during the company's annual shareholders' meeting. He will retire from the board effective as of the date of the meeting. Schenkein is a member of the audit committee.
Apr 12, 2017

Patrick Balthrop

Agendia has appointed Patrick Balthrop, former CEO of Luminex, as non-executive chairman. Balthrop is a director at Oxford Immunotec, Personalis, and Concert Genetics. He's also an advisor to Water Street Healthcare Partners and the Founding Principal of Apalachee Ventures, an investment and advisory firm. 

Apr 05, 2017

Alister Reynolds

Alister Reynolds has agreed to become CEO of SomaLogic. He is replacing Byron Hewett, who is stepping down. Reynolds has been on the company's board since 2003, and has held senior executive positions at Quest Diagnostics and its predecessor Corning.

Apr 05, 2017

Vishal Sikri

Vishal Sikri was appointed the general manager of Biocartis' US subsidiary, Biocartis US. Sikri was managing director and VP of commercial operations at Sysmex Inostics, the molecular diagnostics division of Sysmex, where he held other various roles. Prior to Sysmex, he held different senior product management positions at Abbott Laboratories. 

Apr 04, 2017

Erik Phelps

Tempus has hired Erik Phelps as executive VP and general counsel. He will be responsible for general corporate matters, strategy, and several other legal areas. Phelps comes to Tempus from electronic health records maker Epic Systems, where he also served as general counsel. He holds a JD from George Washington University Law School.

Apr 03, 2017

James Heath

The Institute for Systems Biology named James Heath its new president, effective January 2018. The current President and ISB Cofounder Lee Hood will remain on the institute's board. Heath is the Elizabeth W. Gilloon professor of chemistry at the California Institute of Technology, and a professor of molecular and medical pharmacology and codirector of the Parker Institute for Cancer Immunotherapy at the University of California, Los Angeles. He also is director of the NanoSystems Biology Cancer Center, which is funded by the National Cancer Institute. 

Mar 30, 2017

Joshua LaBaer

Joshua LaBaer has been appointed the executive director of the Biodesign Institute at Arizona State University, effective April 1. He was formerly at Harvard before joining ASU in 2009 to lead personalized medicine efforts at the institute as the university's first Virginia G. Piper Chair of Personalized Medicine, and director of the Biodesign Virginia G. Piper Center for Personalized Diagnostics. 

Mar 30, 2017

Michael Knell, Anthony Mattacchione

Bruker VP of Finance and Chief Accounting Officer Michael Knell announced he is resigning from the firm, effective April 21, in order to pursue other opportunities. Bruker CFO and Senior VP Anthony Mattacchione has assumed Knell's responsibilities as the company's principal accounting officer.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.